ID   MK13_HUMAN              Reviewed;         365 AA.
AC   O15264; O14739; O15124; Q5U4A5; Q6FI46; Q9UNU0;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   15-MAR-2017, entry version 178.
DE   RecName: Full=Mitogen-activated protein kinase 13;
DE            Short=MAP kinase 13;
DE            Short=MAPK 13;
DE            EC=2.7.11.24;
DE   AltName: Full=Mitogen-activated protein kinase p38 delta;
DE            Short=MAP kinase p38 delta;
DE   AltName: Full=Stress-activated protein kinase 4;
GN   Name=MAPK13; Synonyms=PRKM13, SAPK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ENZYME REGULATION.
RC   TISSUE=Pituitary;
RX   PubMed=9218798; DOI=10.1093/emboj/16.12.3563;
RA   Goedert M., Cuenda A., Craxton M., Jakes R., Cohen P.;
RT   "Activation of the novel stress-activated protein kinase SAPK4 by
RT   cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison
RT   of its substrate specificity with that of other SAP kinases.";
RL   EMBO J. 16:3563-3571(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION AT THR-180 AND
RP   TYR-182, MUTAGENESIS OF THR-180 AND TYR-182, ENZYME REGULATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9374491; DOI=10.1074/jbc.272.48.30122;
RA   Jiang Y., Gram H., Zhao M., New L., Gu J., Feng L., Di Padova F.,
RA   Ulevitch R.J., Han J.;
RT   "Characterization of the structure and function of the fourth member
RT   of p38 group mitogen-activated protein kinases, p38delta.";
RL   J. Biol. Chem. 272:30122-30128(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9295308; DOI=10.1074/jbc.272.38.23668;
RA   Wang X.S., Diener K., Manthey C.L., Wang S.-W., Rosenzweig B.,
RA   Bray J., Delaney J., Cole C., Zukowski M., Yao Z.;
RT   "Molecular cloning and characterization of a novel p38 mitogen-
RT   activated protein kinase.";
RL   J. Biol. Chem. 272:23668-23674(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9207191; DOI=10.1006/bbrc.1997.6849;
RA   Kumar S., McDonnell P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R.;
RT   "Novel homologues of CSBP/p38 MAP kinase: activation, substrate
RT   specificity and sensitivity to inhibition by pyridinyl imidazoles.";
RL   Biochem. Biophys. Res. Commun. 235:533-538(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10066767; DOI=10.1074/jbc.274.11.7095;
RA   Hu M.C.-T., Wang Y.-P., Mikhail A., Qiu W.R., Tan T.-H.;
RT   "Murine p38-delta mitogen-activated protein kinase, a developmentally
RT   regulated protein kinase that is activated by stress and
RT   proinflammatory cytokines.";
RL   J. Biol. Chem. 274:7095-7102(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10727080; DOI=10.3109/10425179909033952;
RA   Herbison C.E., Sayer D.C., Bellgard M., Allcock R.J.N.,
RA   Christiansen F.T., Price P.;
RT   "Structure and polymorphism of two stress-activated protein kinase
RT   genes centromeric of the MHC: SAPK2a and SAPK4.";
RL   DNA Seq. 10:229-243(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF STMN1.
RX   PubMed=9731215; DOI=10.1006/bbrc.1998.9250;
RA   Parker C.G., Hunt J., Diener K., McGinley M., Soriano B.,
RA   Keesler G.A., Bray J., Yao Z., Wang X.S., Kohno T., Lichenstein H.S.;
RT   "Identification of stathmin as a novel substrate for p38 delta.";
RL   Biochem. Biophys. Res. Commun. 249:791-796(1998).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=10201954;
RA   Hale K.K., Trollinger D., Rihanek M., Manthey C.L.;
RT   "Differential expression and activation of p38 mitogen-activated
RT   protein kinase alpha, beta, gamma, and delta in inflammatory cell
RT   lineages.";
RL   J. Immunol. 162:4246-4252(1999).
RN   [14]
RP   INTERACTION WITH MAPK8IP2.
RX   PubMed=11378392; DOI=10.1016/S0960-9822(01)00232-9;
RA   Schoorlemmer J., Goldfarb M.;
RT   "Fibroblast growth factor homologous factors are intracellular
RT   signaling proteins.";
RL   Curr. Biol. 11:793-797(2001).
RN   [15]
RP   FUNCTION, AND ENZYME REGULATION.
RX   PubMed=11500363; DOI=10.1093/emboj/20.16.4360;
RA   Knebel A., Morrice N., Cohen P.;
RT   "A novel method to identify protein kinase substrates: eEF2 kinase is
RT   phosphorylated and inhibited by SAPK4/p38delta.";
RL   EMBO J. 20:4360-4369(2001).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=11943212; DOI=10.1016/S0014-5793(02)02460-2;
RA   Buee-Scherrer V., Goedert M.;
RT   "Phosphorylation of microtubule-associated protein tau by stress-
RT   activated protein kinases in intact cells.";
RL   FEBS Lett. 515:151-154(2002).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT.
RX   PubMed=15632108; DOI=10.1242/jcs.01655;
RA   Feijoo C., Campbell D.G., Jakes R., Goedert M., Cuenda A.;
RT   "Evidence that phosphorylation of the microtubule-associated protein
RT   Tau by SAPK4/p38delta at Thr50 promotes microtubule assembly.";
RL   J. Cell Sci. 118:397-408(2005).
RN   [18]
RP   FUNCTION IN KERATINOCYTE APOPTOSIS.
RX   PubMed=17256148; DOI=10.1007/s00403-006-0727-4;
RA   Kraft C.A., Efimova T., Eckert R.L.;
RT   "Activation of PKCdelta and p38delta MAPK during okadaic acid
RT   dependent keratinocyte apoptosis.";
RL   Arch. Dermatol. Res. 299:71-83(2007).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF MYB.
RX   PubMed=18006338; DOI=10.1016/j.bcmd.2007.09.010;
RA   Pani E., Ferrari S.;
RT   "p38MAPK delta controls c-Myb degradation in response to stress.";
RL   Blood Cells Mol. Dis. 40:388-394(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   DEPHOSPHORYLATION BY DUSP1, AND FUNCTION.
RX   PubMed=18367666; DOI=10.1073/pnas.0801453105;
RA   Zhou X., Ferraris J.D., Dmitrieva N.I., Liu Y., Burg M.B.;
RT   "MKP-1 inhibits high NaCl-induced activation of p38 but does not
RT   inhibit the activation of TonEBP/OREBP: opposite roles of p38alpha and
RT   p38delta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5620-5625(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-350, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   FUNCTION.
RX   PubMed=20478268; DOI=10.1016/j.bbrc.2010.05.072;
RA   Ozawa S., Ito S., Kato Y., Kubota E., Hata R.;
RT   "Human p38 delta MAP kinase mediates UV irradiation induced up-
RT   regulation of the gene expression of chemokine BRAK/CXCL14.";
RL   Biochem. Biophys. Res. Commun. 396:1060-1064(2010).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=20090411; DOI=10.4161/cc.9.3.10541;
RA   Efimova T.;
RT   "p38delta mitogen-activated protein kinase regulates skin homeostasis
RT   and tumorigenesis.";
RL   Cell Cycle 9:498-505(2010).
RN   [25]
RP   REVIEW ON ENZYME REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=20626350; DOI=10.1042/BJ20100323;
RA   Cuadrado A., Nebreda A.R.;
RT   "Mechanisms and functions of p38 MAPK signalling.";
RL   Biochem. J. 429:403-417(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 2-352.
RG   New York structural genomix research consortium (NYSGXRC);
RT   "Crystal structure of p38delta kinase.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-41; VAL-282 AND THR-300.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential
CC       component of the MAP kinase signal transduction pathway. MAPK13 is
CC       one of the four p38 MAPKs which play an important role in the
CC       cascades of cellular responses evoked by extracellular stimuli
CC       such as proinflammatory cytokines or physical stress leading to
CC       direct activation of transcription factors such as ELK1 and ATF2.
CC       Accordingly, p38 MAPKs phosphorylate a broad range of proteins and
CC       it has been estimated that they may have approximately 200 to 300
CC       substrates each. MAPK13 is one of the less studied p38 MAPK
CC       isoforms. Some of the targets are downstream kinases such as
CC       MAPKAPK2, which are activated through phosphorylation and further
CC       phosphorylate additional targets. Plays a role in the regulation
CC       of protein translation by phosphorylating and inactivating EEF2K.
CC       Involved in cytoskeletal remodeling through phosphorylation of
CC       MAPT and STMN1. Mediates UV irradiation induced up-regulation of
CC       the gene expression of CXCL14. Plays an important role in the
CC       regulation of epidermal keratinocyte differentiation, apoptosis
CC       and skin tumor development. Phosphorylates the transcriptional
CC       activator MYB in response to stress which leads to rapid MYB
CC       degradation via a proteasome-dependent pathway. MAPK13 also
CC       phosphorylates and down-regulates PRKD1 during regulation of
CC       insulin secretion in pancreatic beta cells.
CC       {ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:11943212,
CC       ECO:0000269|PubMed:15632108, ECO:0000269|PubMed:17256148,
CC       ECO:0000269|PubMed:18006338, ECO:0000269|PubMed:18367666,
CC       ECO:0000269|PubMed:20478268, ECO:0000269|PubMed:9731215}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Activated by phosphorylation on threonine and
CC       tyrosine by dual specificity kinases, MAP2K3/MKK3, MAP2K6/MKK6,
CC       MAP2K4/MKK4 and MAP2K7/MKK7. Activation by ultraviolet radiation,
CC       hyperosmotic shock, anisomycin or by TNF-alpha is mediated by
CC       MAP2K3/MKK3. Inhibited by dual specificity phosphatase DUSP1.
CC       {ECO:0000269|PubMed:11500363, ECO:0000269|PubMed:9218798,
CC       ECO:0000269|PubMed:9374491}.
CC   -!- SUBUNIT: Interacts with MAPK8IP2. {ECO:0000269|PubMed:11378392}.
CC   -!- INTERACTION:
CC       P21462:FPR1; NbExp=3; IntAct=EBI-2116951, EBI-2869495;
CC       Q15139:PRKD1; NbExp=6; IntAct=EBI-2116951, EBI-1181072;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15264-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15264-2; Sequence=VSP_056558, VSP_056559;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in testes, pancreas, small
CC       intestine, lung and kidney. Abundant in macrophages, also present
CC       in neutrophils, CD4+ T-cells, and endothelial cells.
CC       {ECO:0000269|PubMed:10201954, ECO:0000269|PubMed:9374491}.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-180 and Tyr-182 by MAP2K3/MKK3,
CC       MAP2K4/MKK4, MAP2K6/MKK6 and MAP2K7/MKK7, which activates the
CC       enzyme. Dephosphorylated by dual specificity phosphatase DUSP1.
CC       {ECO:0000269|PubMed:9374491}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. MAP kinase subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAPK13ID41291ch6p21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y10488; CAA71512.1; -; mRNA.
DR   EMBL; U93232; AAB87639.1; -; mRNA.
DR   EMBL; AF015256; AAC51758.1; -; mRNA.
DR   EMBL; AF004709; AAC51374.1; -; mRNA.
DR   EMBL; AF092535; AAD23377.1; -; mRNA.
DR   EMBL; AF100546; AAF36772.1; -; mRNA.
DR   EMBL; BT007221; AAP35885.1; -; mRNA.
DR   EMBL; CR536490; CAG38729.1; -; mRNA.
DR   EMBL; Z95152; CAB08438.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03874.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03875.1; -; Genomic_DNA.
DR   EMBL; BC000433; AAH00433.1; -; mRNA.
DR   EMBL; BC001641; AAH01641.1; -; mRNA.
DR   EMBL; BC004428; AAH04428.1; -; mRNA.
DR   EMBL; BC085196; AAH85196.1; -; mRNA.
DR   CCDS; CCDS4818.1; -. [O15264-1]
DR   PIR; JC5528; JC5528.
DR   RefSeq; NP_002745.1; NM_002754.4. [O15264-1]
DR   UniGene; Hs.178695; -.
DR   PDB; 3COI; X-ray; 2.09 A; A=2-352.
DR   PDB; 4EYJ; X-ray; 2.10 A; A=1-352.
DR   PDB; 4EYM; X-ray; 2.35 A; A=1-352.
DR   PDB; 4MYG; X-ray; 2.59 A; A/B=1-352.
DR   PDB; 4YNO; X-ray; 1.70 A; A=1-352.
DR   PDB; 5EKN; X-ray; 2.59 A; A=1-352.
DR   PDB; 5EKO; X-ray; 2.00 A; A=1-352.
DR   PDBsum; 3COI; -.
DR   PDBsum; 4EYJ; -.
DR   PDBsum; 4EYM; -.
DR   PDBsum; 4MYG; -.
DR   PDBsum; 4YNO; -.
DR   PDBsum; 5EKN; -.
DR   PDBsum; 5EKO; -.
DR   ProteinModelPortal; O15264; -.
DR   SMR; O15264; -.
DR   BioGrid; 111589; 17.
DR   IntAct; O15264; 90.
DR   MINT; MINT-1183220; -.
DR   STRING; 9606.ENSP00000211287; -.
DR   BindingDB; O15264; -.
DR   ChEMBL; CHEMBL2939; -.
DR   DrugBank; DB05157; KC706.
DR   GuidetoPHARMACOLOGY; 1502; -.
DR   iPTMnet; O15264; -.
DR   PhosphoSitePlus; O15264; -.
DR   BioMuta; MAPK13; -.
DR   EPD; O15264; -.
DR   MaxQB; O15264; -.
DR   PaxDb; O15264; -.
DR   PeptideAtlas; O15264; -.
DR   PRIDE; O15264; -.
DR   DNASU; 5603; -.
DR   Ensembl; ENST00000211287; ENSP00000211287; ENSG00000156711. [O15264-1]
DR   Ensembl; ENST00000373766; ENSP00000362871; ENSG00000156711. [O15264-2]
DR   GeneID; 5603; -.
DR   KEGG; hsa:5603; -.
DR   UCSC; uc003ols.5; human. [O15264-1]
DR   CTD; 5603; -.
DR   DisGeNET; 5603; -.
DR   GeneCards; MAPK13; -.
DR   HGNC; HGNC:6875; MAPK13.
DR   HPA; CAB025854; -.
DR   HPA; HPA007667; -.
DR   MIM; 602899; gene.
DR   neXtProt; NX_O15264; -.
DR   OpenTargets; ENSG00000156711; -.
DR   PharmGKB; PA30620; -.
DR   eggNOG; KOG0660; Eukaryota.
DR   eggNOG; ENOG410XNY0; LUCA.
DR   GeneTree; ENSGT00550000074271; -.
DR   HOGENOM; HOG000233024; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; O15264; -.
DR   KO; K04441; -.
DR   OMA; EHPYFDN; -.
DR   OrthoDB; EOG091G08QL; -.
DR   PhylomeDB; O15264; -.
DR   TreeFam; TF105100; -.
DR   BRENDA; 2.7.11.24; 2681.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-171007; p38MAPK events.
DR   Reactome; R-HSA-376172; DSCAM interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   SignaLink; O15264; -.
DR   SIGNOR; O15264; -.
DR   EvolutionaryTrace; O15264; -.
DR   GeneWiki; MAPK13; -.
DR   GenomeRNAi; 5603; -.
DR   PRO; PR:O15264; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000156711; -.
DR   CleanEx; HS_MAPK13; -.
DR   ExpressionAtlas; O15264; baseline and differential.
DR   Genevisible; O15264; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IMP:BHF-UCL.
DR   GO; GO:0010468; P:regulation of gene expression; IBA:GO_Central.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006970; P:response to osmotic stress; IDA:UniProtKB.
DR   GO; GO:0006950; P:response to stress; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008352; MAPK_p38.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01773; P38MAPKINASE.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Complete proteome; Kinase; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Stress response; Transcription; Transcription regulation; Transferase.
FT   CHAIN         1    365       Mitogen-activated protein kinase 13.
FT                                /FTId=PRO_0000186286.
FT   DOMAIN       25    308       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      31     39       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       180    182       TXY.
FT   ACT_SITE    150    150       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING      54     54       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      47     47       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087}.
FT   MOD_RES     180    180       Phosphothreonine; by MAP2K3, MAP2K4,
FT                                MAP2K6 and MAP2K7.
FT                                {ECO:0000269|PubMed:9374491}.
FT   MOD_RES     182    182       Phosphotyrosine; by MAP2K3, MAP2K4,
FT                                MAP2K6 and MAP2K7.
FT                                {ECO:0000269|PubMed:9374491}.
FT   MOD_RES     350    350       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   VAR_SEQ     204    256       VDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGT
FT                                EFVQKLNDKAAK -> GQILHPVPATDPQEGFHSAVPTGQP
FT                                PGCGPAGEDAGARRGQAPDGRAGPHPSL (in isoform
FT                                2). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056558.
FT   VAR_SEQ     257    364       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056559.
FT   VARIANT      41     41       S -> L (in dbSNP:rs55776345).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042267.
FT   VARIANT     282    282       A -> V (in dbSNP:rs55990045).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042268.
FT   VARIANT     300    300       A -> T (in dbSNP:rs41270090).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042269.
FT   MUTAGEN     180    180       T->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9374491}.
FT   MUTAGEN     182    182       Y->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:9374491}.
FT   CONFLICT     13     14       DV -> EL (in Ref. 4; AAC51374).
FT                                {ECO:0000305}.
FT   CONFLICT     39     39       V -> W (in Ref. 4; AAC51374).
FT                                {ECO:0000305}.
FT   CONFLICT     56     56       L -> P (in Ref. 3; AAC51758).
FT                                {ECO:0000305}.
FT   CONFLICT    166    166       I -> V (in Ref. 3; AAC51758).
FT                                {ECO:0000305}.
FT   CONFLICT    224    224       K -> R (in Ref. 3; AAC51758 and 5;
FT                                AAD23377). {ECO:0000305}.
FT   HELIX         4      8       {ECO:0000244|PDB:3COI}.
FT   STRAND        9     14       {ECO:0000244|PDB:4YNO}.
FT   STRAND       17     22       {ECO:0000244|PDB:4YNO}.
FT   STRAND       25     33       {ECO:0000244|PDB:4YNO}.
FT   STRAND       35     44       {ECO:0000244|PDB:4YNO}.
FT   TURN         45     47       {ECO:0000244|PDB:4YNO}.
FT   STRAND       50     56       {ECO:0000244|PDB:4YNO}.
FT   HELIX        63     78       {ECO:0000244|PDB:4YNO}.
FT   STRAND       88     91       {ECO:0000244|PDB:4YNO}.
FT   STRAND       95     97       {ECO:0000244|PDB:4YNO}.
FT   STRAND      104    108       {ECO:0000244|PDB:4YNO}.
FT   STRAND      111    113       {ECO:0000244|PDB:3COI}.
FT   HELIX       114    117       {ECO:0000244|PDB:4YNO}.
FT   HELIX       124    143       {ECO:0000244|PDB:4YNO}.
FT   HELIX       153    155       {ECO:0000244|PDB:4YNO}.
FT   STRAND      156    158       {ECO:0000244|PDB:4YNO}.
FT   STRAND      164    166       {ECO:0000244|PDB:4YNO}.
FT   HELIX       186    188       {ECO:0000244|PDB:4MYG}.
FT   HELIX       191    195       {ECO:0000244|PDB:4YNO}.
FT   TURN        196    198       {ECO:0000244|PDB:4MYG}.
FT   HELIX       204    218       {ECO:0000244|PDB:4YNO}.
FT   STRAND      222    226       {ECO:0000244|PDB:3COI}.
FT   HELIX       228    239       {ECO:0000244|PDB:4YNO}.
FT   HELIX       244    247       {ECO:0000244|PDB:4YNO}.
FT   HELIX       253    261       {ECO:0000244|PDB:4YNO}.
FT   HELIX       270    273       {ECO:0000244|PDB:4YNO}.
FT   HELIX       279    288       {ECO:0000244|PDB:4YNO}.
FT   TURN        293    295       {ECO:0000244|PDB:4YNO}.
FT   HELIX       299    303       {ECO:0000244|PDB:4YNO}.
FT   HELIX       306    308       {ECO:0000244|PDB:4YNO}.
FT   TURN        309    311       {ECO:0000244|PDB:4YNO}.
FT   HELIX       314    316       {ECO:0000244|PDB:4YNO}.
FT   HELIX       327    329       {ECO:0000244|PDB:4YNO}.
FT   HELIX       335    347       {ECO:0000244|PDB:4YNO}.
SQ   SEQUENCE   365 AA;  42090 MW;  52E749EDB2973DDF CRC64;
     MSLIRKKGFY KQDVNKTAWE LPKTYVSPTH VGSGAYGSVC SAIDKRSGEK VAIKKLSRPF
     QSEIFAKRAY RELLLLKHMQ HENVIGLLDV FTPASSLRNF YDFYLVMPFM QTDLQKIMGM
     EFSEEKIQYL VYQMLKGLKY IHSAGVVHRD LKPGNLAVNE DCELKILDFG LARHADAEMT
     GYVVTRWYRA PEVILSWMHY NQTVDIWSVG CIMAEMLTGK TLFKGKDYLD QLTQILKVTG
     VPGTEFVQKL NDKAAKSYIQ SLPQTPRKDF TQLFPRASPQ AADLLEKMLE LDVDKRLTAA
     QALTHPFFEP FRDPEEETEA QQPFDDSLEH EKLTVDEWKQ HIYKEIVNFS PIARKDSRRR
     SGMKL
//
